89bio, Inc(NASDAQ:ETNB) 
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalc...
Website: http://www.89bio.com
Founded: 2018
IPO Price: $16 (Nov 11, 2019)
Full Time Employees: 25
CEO: Rohan Palekar
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 6.58
H 6.80
L 5.55
C 5.77
V 3,497,246
10EMA 5.77
20EMA 5.77
60EMA 5.77
120EMA 5.77
250EMA 5.77